Use of ANAR for the therapy of opium withdrawal syndrome

We studied the efficiency of ANAR containing antibodies to morphine (dilutions C300 and C200) in the therapy of patients with the opium withdrawal syndrome. In patients with moderate to severe forms of the opium withdrawal syndrome therapeutic activity of ANAR was comparable to that of standard symp...

Full description

Saved in:
Bibliographic Details
Published inBulletin of experimental biology and medicine Vol. 135 Suppl 7; p. 181
Main Authors Gofman, A G, Krylov, E N, Kozhinova, T A, Nizhnichenko, T I, Khanykov, V V, Sheveleva, O S, Epstein, O I, Yashkina, I V
Format Journal Article
LanguageEnglish
Published United States Springer Nature B.V 2003
Subjects
Adult
Analgesics - immunology
Analgesics - therapeutic use
Antibodies - immunology
Antibodies - therapeutic use
Humans
Hypnotics and Sedatives - immunology
Hypnotics and Sedatives - therapeutic use
Morphine - immunology
Opioid-Related Disorders - drug therapy
Opium
Substance Withdrawal Syndrome - drug therapy
Treatment Outcome
Young Adult
Online AccessGet full text

Cover

More Information
Summary:We studied the efficiency of ANAR containing antibodies to morphine (dilutions C300 and C200) in the therapy of patients with the opium withdrawal syndrome. In patients with moderate to severe forms of the opium withdrawal syndrome therapeutic activity of ANAR was comparable to that of standard symptomatic drugs. ANAR possessed vegetostabilizing, sedative, and analgetic properties. Treatment with ANAR allowed us to reduce doses of psychotropic and analgetic preparations and delay the development of withdrawal symptoms by 18-24 h.
ISSN:0007-4888
1573-8221
DOI:10.1023/A:1024713115392